| 17.02 0.18 (1.07%) | 01-29 14:40 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.1 | 1-year : | 24.65 |
| Resists | First : | 18.06 | Second : | 21.1 |
| Pivot price | 15.98  |
|||
| Supports | First : | 14.75 |
Second : | 12.69 |
| MAs | MA(5) : | 17.04  |
MA(20) : | 15.39 |
| MA(100) : | 12.55 |
MA(250) : | 9.54 |
|
| MACD | MACD : | 1.1 |
Signal : | 1 |
| %K %D | K(14,3) : | 81.5 |
D(3) : | 80.4 |
| RSI | RSI(14): 62.6 |
|||
| 52-week | High : | 18.06 | Low : | 4.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MNMD ] has closed below upper band by 30.5%. Bollinger Bands are 104.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.42 - 17.54 | 17.54 - 17.63 |
| Low: | 16.28 - 16.4 | 16.4 - 16.5 |
| Close: | 16.85 - 17.05 | 17.05 - 17.21 |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Wed, 14 Jan 2026
Mind Medicine (MNMD) Price Target Increased by 11.49% to 29.15 - Nasdaq
Tue, 13 Jan 2026
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD) - Sahm
Mon, 12 Jan 2026
Definium points the way forward as MindMed drops old identity - Fierce Pharma
Sat, 27 Dec 2025
What’s Driving JonesTrading’s Bullish View on Mind Medicine (MindMed) Inc. (MNMD) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 41.6 (%) |
| Shares Short | 15,050 (K) |
| Shares Short P.Month | 12,350 (K) |
| EPS | -1.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | -85.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -114 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -8.6 |
| PEG Ratio | 0 |
| Price to Book value | 10.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|